Ausgabe 1/2014
Inhalt (24 Artikel)
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
Aristoteles Giagounidis, Ghulam J. Mufti, Pierre Fenaux, Ulrich Germing, Alan List, Kyle J. MacBeth
Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Sabine Mousset, Dieter Buchheidt, Werner Heinz, Markus Ruhnke, Oliver A. Cornely, Gerlinde Egerer, William Krüger, Hartmut Link, Silke Neumann, Helmut Ostermann, Jens Panse, Olaf Penack, Christina Rieger, Martin Schmidt-Hieber, Gerda Silling, Thomas Südhoff, Andrew J. Ullmann, Hans-Heinrich Wolf, Georg Maschmeyer, Angelika Böhme
The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in Korea
Jin Seok Kim, June-Won Cheong, Yeo-Kyeoung Kim, Jinny Park, Yeung-Chul Mun, Hye Jin Kang, Hyeon Gyu Yi, Je-Hwan Lee, Yang Soo Kim, Hun-Mo Ryoo, Sung-Hyun Kim, Ho Young Kim, Jin Young Kim, Dong-Gun Lee, Hoon-Gu Kim, Hawk Kim, Young-Don Joo, Yoo Hong Min
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia
David Martínez-Cuadrón, Pau Montesinos, Albert Oriol, Olga Salamero, Belén Vidriales, Juan Bergua, Pilar Herrera, Susanna Vives, Jaime Sanz, Cecilia Carpio, Rebeca Rodríguez-Veiga, Federico Moscardó, Miguel A. Sanz
Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
Bernard Tawfik, Sarunas Sliesoraitis, Susan Lyerly, Heidi D. Klepin, Julia Lawrence, Scott Isom, Leslie R. Ellis, Megan Manuel, Sarah Dralle, Dmitriy Berenzon, Bayard L. Powell, Timothy Pardee
Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis
Sigrid Machherndl-Spandl, W. Sega, H. Bösmüller, U. Germing, Ch. Gruber, K. Nachtkamp, P. Reinecke, W. R. Sperr, F. Wimazal, L. Müllauer, K. Sotlar, H. P. Horny, H. Tüchler, P. Valent, O. Krieger
Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow
Judith Neukirchen, Uwe Platzbecker, Katja Sockel, Antonis Tsamaloukas, Rainer Haas, Ulrich Germing
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV
Lida Kalmanti, Susanne Saussele, Michael Lauseker, Ulrike Proetel, Martin C. Müller, Benjamin Hanfstein, Annette Schreiber, Alice Fabarius, Markus Pfirrmann, Susanne Schnittger, Jolanta Dengler, Christiane Falge, Lothar Kanz, Andreas Neubauer, Frank Stegelmann, Michael Pfreundschuh, Cornelius F. Waller, Karsten Spiekermann, Stefan W. Krause, Dominik Heim, Christoph Nerl, Dieter K. Hossfeld, Hans-Jochem Kolb, Andreas Hochhaus, Joerg Hasford, Rüdiger Hehlmann
The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis
Philipp Erben, Juliana Schwaab, Georgia Metzgeroth, Hans-Peter Horny, Mohamad Jawhar, Karl Sotlar, Alice Fabarius, Martina Teichmann, Sven Schneider, Thomas Ernst, Martin C. Müller, Michelle Giehl, Alexander Marx, Karin Hartmann, Andreas Hochhaus, Wolf-Karsten Hofmann, Nicholas C. P. Cross, Andreas Reiter
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
James R. Berenson, James D. Hilger, Ori Yellin, Ralph V. Boccia, Jeffrey Matous, Kenneth Dressler, Hassan H. Ghazal, Saad Jamshed, Edwin C. Kingsley, Wael A. Harb, Stephen J. Noga, Youram Nassir, Regina A. Swift, Robert Vescio
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Silvia Park, Su Jin Lee, Chul Won Jung, Jun Ho Jang, Seok Jin Kim, Won Seog Kim, Kihyun Kim
Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma
Natalia Tovar, Carlos Fernández de Larrea, Fabiola Pedrosa, Juan I. Aróstegui, Ma. Teresa Cibeira, Laura Rosiñol, Montserrat Elena, Xavier Filella, Jordi Yagüe, Joan Bladé
Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea—experience from 110 patients
Kihyun Kim, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung-Soo Yoon, Je-Jung Lee, Jae-Yong Kwak, Hun-Mo Ryoo, Yang Soo Kim, Joon Ho Moon, Seong Kyu Park, Sung-Hyun Kim, Yeung-Chul Mun, Jin Seok Kim, Hyeon-Seok Eom, Deog-Yeon Jo, Hyun Jung Jun, Ki-Hwan Kim, Jeong-Ok Lee, Jae Hoon Lee, Chang-Ki Min
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes
Lucia Pantani, Elena Zamagni, Beatrice Anna Zannetti, Annalisa Pezzi, Paola Tacchetti, Annamaria Brioli, Katia Mancuso, Giulia Perrone, Serena Rocchi, Patrizia Tosi, Michele Cavo
“Real-world” data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group
Eirini Katodritou, Chrysanthi Vadikolia, Chrysavgi Lalagianni, Maria Kotsopoulou, Georgia Papageorgiou, Marie-Christine Kyrtsonis, Panagiota Matsouka, Nikolaos Giannakoulas, Despoina Kyriakou, Georgios Karras, Nikolaos Anagnostopoulos, Evridiki Michali, Evangelos Briasoulis, Eleftheria Hatzimichael, Emmanouil Spanoudakis, Panagiotis Zikos, Anastasia Tsakiridou, Konstantinos Tsionos, Konstantinos Anargyrou, Argiris Symeonidis, Alice Maniatis, Evangelos Terpos
Multiple myeloma: a descriptive study of 217 Egyptian patients
Noha M. El Husseiny, Neemat Kasem, Hamdy Abd El Azeeim, Mervat W. Mattar
Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years’ experience in a single centre
Sinziana Radesi-Sarghi, Flavie Arbion, Caroline Dartigeas, Martine Delain, Lotfi Benboubker, Olivier Hérault, Philippe Colombat, Emmanuel Gyan
Increased risk of chronic lymphocytic leukaemia among cancer survivors in the Netherlands: increased detection, causal factors or both?
E. C. van den Broek, L. Liu, E. F. M. Posthuma, M. L. G. Janssen-Heijnen, J. W. W. Coebergh, I. Soerjomataram
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations
Massimiliano Bonifacio, Gianni Binotto, Elisabetta Calistri, Elena Maino, Mario Tiribelli
No difference between posaconazole and fluconazole antifungal prophylaxis and mycological diagnostics except costs in patients undergoing AML chemotherapy: a 1-year "real-life" evaluation
Hartmut Bertz, Kathrin Drognitz, Michael Lübbert
Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies
Yasuyo Ohyama, Takahiro Kumode, Go Eguchi, Terufumi Yamaguchi, Yasuhiro Maeda
An atypical manifestation of acquired von Willebrand syndrome (AVWS) associated with systemic lupus erythematosus (SLE)
Priyanka Kasatkar, Kanjaksha Ghosh, Shrimati Shetty
Burkitt lymphomas failing dose-adjusted R-EPOCH (DA-R-EPOCH)
Igor Aurer, Sandra Bašić-Kinda, Ivo Radman, Ivana Ilić, Josip Joachim Grah
MtDNA depletion and deletions may also have a role in myelodysplastic syndrome
Tuncer Cayci, Bulent Kurt, Yasemin Gulcan Kurt, Emin Ozgur Akgul